Press Releases

Date Title  
Toggle Summary Published Study Demonstrates Natera's Ability to Identify Heterogeneous Cancer Mutations in Patients with Early-Stage Lung Cancer
Analysis of liquid biopsies can detect mutations that may be missed in tumor tissue biopsies SAN CARLOS, Calif. , March 7, 2016 /PRNewswire/ --  Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced a study published in
Toggle Summary Natera to Present at the Cowen and Company 36th Annual Health Care Conference
SAN CARLOS, Calif. , March 3, 2016 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will present at the Cowen and Company 36th Annual Health Care Conference in Boston on Wednesday, March 9,
Toggle Summary Natera to Release Fourth Quarter and Fiscal Year 2015 Financial Results
SAN CARLOS, Calif. , March 2, 2016 /PRNewswire/ - Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its fourth quarter and year ended December 31, 2015 after the market close on March
Toggle Summary Genetica Now Offering PanoramaTM NIPT in Switzerland via Natera's Constellation™ Software Platform
SAN CARLOS, Calif. , Feb. 9, 2016 /PRNewswire/ -- Natera, Inc., (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that Genetica, a leading laboratory for prenatal diagnostics in Switzerland , is now performing the Panorama non-invasive
Toggle Summary Large-Scale Clinical Study Shows Panorama® Prenatal Screen to be Highly Accurate in Identifying 22q11.2 Deletion Syndrome in a General Population
Clinical evidence supports screening for 22q.11.2 in the general population SAN CARLOS, Calif. , Jan. 12, 2016 /PRNewswire/ --  Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and analysis of circulating cell-free DNA, today announced the publication of the first major
Toggle Summary MedGenome Now Offering Panorama™ NIPT in India via Natera's Constellation™ Cloud-based Software Platform
SAN CARLOS, Calif. , Dec. 18, 2015 /PRNewswire/ --  Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that MedGenome, a leader in clinical genomic testing and a provider of genomic solutions for personalized
Toggle Summary Natera Announces the Appointment of Michael C. Little as Senior Vice President, R&D
SAN CARLOS, Calif. , Dec. 4, 2015 /PRNewswire/ --  Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that Michael C. Little , Ph.D. has joined the company as Senior Vice President, Research and Development.
Toggle Summary Natera to Present at the 27th Annual Piper Jaffray Health Conference
SAN CARLOS, Calif. , Nov. 24, 2015 /PRNewswire/ --  Natera, Inc. (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will present at the 27 th  Annual Piper Jaffray Health Conference in New York on Wednesday, December 2,
Toggle Summary Natera Announces the Appointment of Jimmy Lin as Chief Scientific Officer for Oncology
SAN CARLOS, Calif. , Nov. 19, 2015 /PRNewswire/ -- Natera, Inc., (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that Jimmy Lin , MD, PhD, MHS has been appointed as Chief Scientific Officer for Oncology. Dr.
Toggle Summary Natera Reports Third Quarter 2015 Financial Results
SAN CARLOS, Calif. , Nov. 12,  2015 /PRNewswire/ --  Natera,  Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis  of circulating cell-free DNA, today reported financial results for the third quarter ended September 30, 2015 and provided an update on recent business

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.